ZJ 43

Key Product Details

Product Description

ZJ 43 is a potent inhibitor of glutamate carboxypeptidase II and III (GCP II and III/NAAG peptidase/NAALADase) (K_i values are 0.8 and 23 nM respectively) that inhibits the hydrolysis of NAAG (IC₅₀ = 2.4 nM). Does not directly interact with NMDA or metabotropic glutamate receptors. Reduces neuronal degeneration in a rat model of traumatic brain injury (TBI) and reduces locomotor activity in the PCP-model of schizophrenia.

Licensing Information

Sold with the permission of Acenta Discovery, Inc.

Product Specifications for ZJ 43

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for ZJ 43

The following data is based on the product molecular weight 304.30.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

4 3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.29 mL	16.43 mL	32.86 mL
5 mM	0.66 mL	3.29 mL	6.57 mL
10 mM	0.33 mL	1.64 mL	3.29 mL
50 mM	0.07 mL	0.33 mL	0.66 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 12 publications citing the usage of this product.

• Zhou NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat.Rev.Drug Discov. 2005 PMID: 16341066
• Yamamoto Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats. Eur.J.Neurosci. 2007 PMID: 17241276
• Olszewski NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J.Neurochem. 2004 PMID: 15140187

Product Documents for ZJ 43